Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 16/20 | 0.67 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.67 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.54 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.51 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.51 |
| ▸ | AR | P10275 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL760692 | 0.96 | ESR1 (0.60) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL20821889 | 0.90 | ESR1 (0.55) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL18388215 | 0.88 | ESR1 (0.52) | ESR1ESR2HSD17B1HSD17B2AR | |
| SCHEMBL1254675 | 0.88 | ESR1 (0.52) | ESR1ESR2HSD17B1HSD17B2AR | |
| SCHEMBL7858240 | 0.86 | ESR1 (0.69) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL16982143 | 0.84 | ESR2 (0.67) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL3440740 | 0.83 | ESR1 (0.60) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL28226426 | 0.83 | ESR1 (0.70) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL38659424 | 0.83 | ESR1 (0.70) | ESR1ESR2HSD17B1HSD17B2FGFR1 | |
| SCHEMBL18162325 | 0.81 | ESR1 (0.62) | ESR1ESR2HSD17B1HSD17B2FGFR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2116522-B1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| EP-2116522-B1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | JNC CORP (JP) | 2013-09-18 | — | — | EP | disclosed |
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-7951433-B2 | Five-ring liquid crystal compound having CF2O bonding group, liquid crystal composition, and liquid crystal display device | CHISSO CORPORATION (JP) | 2011-05-31 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-2116522-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
| EP-2116522-A1 | PENTACYCLIC LIQUID CRYSTAL COMPOUND HAVING CF<SB>2</SB>O BONDING GROUP, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY | Chisso Corporation (JP) | 2009-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100127211-A1 | FIVE-RING LIQUID CRYSTAL COMPOUND HAVING CF20 BONDING GROUP, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CFAP20, KIF20A, KIF20B | ESR1 3213/4885ESR2 4095/4885HSD17B1 373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.